For patients managing chronic inflammation as part of a broader longevity strategy, BPC-157 may fit alongside compounds like Low Dose Naltrexone (LDN), which modulates immune activity through a separate mechanism involving endorphin and toll-like receptor signaling, and metabolic interventions that address the upstream drivers of inflammaging
People with digestive issues Conditions like coeliac disease, Crohns disease, or IBS
Chronic low-grade inflammation, often called "inflammaging," is now recognized as a central driver of biological aging, contributing to cardiovascular disease, neurodegeneration, insulin resistance, and loss of muscle mass
This ensures accurate dosing and efficiency
Your prescribing provider determines the schedule based on your specific therapeutic goal and cycle structure
Lyophilised powder